Cargando…
Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients
BACKGROUND: The aim was to examine the feasibility, acceptability and clinical utility of electronic symptom surveillance with clinician feedback using a subset of items drawn from the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a cancer treatme...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934932/ https://www.ncbi.nlm.nih.gov/pubmed/29757324 http://dx.doi.org/10.1186/s41687-017-0005-6 |
_version_ | 1783320211922878464 |
---|---|
author | Baeksted, Christina Pappot, Helle Nissen, Aase Hjollund, Niels Henrik Mitchell, Sandra A. Basch, Ethan Bidstrup, Pernille Envold Dalton, Susanne Oksbjerg Johansen, Christoffer |
author_facet | Baeksted, Christina Pappot, Helle Nissen, Aase Hjollund, Niels Henrik Mitchell, Sandra A. Basch, Ethan Bidstrup, Pernille Envold Dalton, Susanne Oksbjerg Johansen, Christoffer |
author_sort | Baeksted, Christina |
collection | PubMed |
description | BACKGROUND: The aim was to examine the feasibility, acceptability and clinical utility of electronic symptom surveillance with clinician feedback using a subset of items drawn from the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a cancer treatment setting. METHODS: Danish-speaking men with castration-resistant metastatic prostate cancer receiving treatment at the Department of Oncology, Rigshospitalet, Copenhagen between March 9, 2015 and June 8, 2015 were invited to participate (n = 63 eligible). Participants completed the PRO-CTCAE questionnaire on tablet computers using AmbuFlex software at each treatment visit in the outpatient clinic. In total, 22 symptomatic toxicities (41 PRO-CTCAE items), corresponding to the symptomatic adverse-events profile associated with the regimens commonly used for prostate cancer treatment (Docetaxel, Cabazitaxel, Abiraterone, Alpharadin), were selected. Participants’ PRO-CTCAE responses were presented graphically to their treating oncologists via an AmbuFlex dashboard, for real-time use to enhance the patient-clinician dialogue that occurs during the consultation prior to each treatment cycle. Technical and clinical barriers and acceptability were evaluated through semi-structured interviews with both patients and oncologists. Patients receiving active treatment at the end of the study period completed an evaluation questionnaire. RESULTS: Fifty-four out of sixty-three (86%) eligible patients were enrolled. The PRO-CTCAE questionnaire was completed a total of 168 times by 54 participants (median number per patient was 3, range 1–5). Eight surveys were missed, resulting in a compliance rate of 97%. At the end of the study period, 35 patients (65%) were still receiving active treatment and completed the evaluation questionnaire. Patients reported that their PRO-CTCAE responses served as a communication tool. Oncologists stated that the availability of the PRO-CTCAE self-reports during the consultation improved patient-clinician communication about side effects. CONCLUSION: Electronic capture of symptomatic toxicities using PRO-CTCAE and the submission of self-reports to clinicians prior to consultation were feasible among metastatic prostate cancer patients receiving chemotherapy in an outpatient setting, and this procedure was acceptable to both patients and clinicians. Continued research, including a cluster-randomized trial, will evaluate the effects of submitting patients’ PRO-CTCAE results to clinicians prior to consultation on the quality of side-effects management and resultant clinical outcomes. |
format | Online Article Text |
id | pubmed-5934932 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-59349322018-05-09 Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients Baeksted, Christina Pappot, Helle Nissen, Aase Hjollund, Niels Henrik Mitchell, Sandra A. Basch, Ethan Bidstrup, Pernille Envold Dalton, Susanne Oksbjerg Johansen, Christoffer J Patient Rep Outcomes Research BACKGROUND: The aim was to examine the feasibility, acceptability and clinical utility of electronic symptom surveillance with clinician feedback using a subset of items drawn from the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a cancer treatment setting. METHODS: Danish-speaking men with castration-resistant metastatic prostate cancer receiving treatment at the Department of Oncology, Rigshospitalet, Copenhagen between March 9, 2015 and June 8, 2015 were invited to participate (n = 63 eligible). Participants completed the PRO-CTCAE questionnaire on tablet computers using AmbuFlex software at each treatment visit in the outpatient clinic. In total, 22 symptomatic toxicities (41 PRO-CTCAE items), corresponding to the symptomatic adverse-events profile associated with the regimens commonly used for prostate cancer treatment (Docetaxel, Cabazitaxel, Abiraterone, Alpharadin), were selected. Participants’ PRO-CTCAE responses were presented graphically to their treating oncologists via an AmbuFlex dashboard, for real-time use to enhance the patient-clinician dialogue that occurs during the consultation prior to each treatment cycle. Technical and clinical barriers and acceptability were evaluated through semi-structured interviews with both patients and oncologists. Patients receiving active treatment at the end of the study period completed an evaluation questionnaire. RESULTS: Fifty-four out of sixty-three (86%) eligible patients were enrolled. The PRO-CTCAE questionnaire was completed a total of 168 times by 54 participants (median number per patient was 3, range 1–5). Eight surveys were missed, resulting in a compliance rate of 97%. At the end of the study period, 35 patients (65%) were still receiving active treatment and completed the evaluation questionnaire. Patients reported that their PRO-CTCAE responses served as a communication tool. Oncologists stated that the availability of the PRO-CTCAE self-reports during the consultation improved patient-clinician communication about side effects. CONCLUSION: Electronic capture of symptomatic toxicities using PRO-CTCAE and the submission of self-reports to clinicians prior to consultation were feasible among metastatic prostate cancer patients receiving chemotherapy in an outpatient setting, and this procedure was acceptable to both patients and clinicians. Continued research, including a cluster-randomized trial, will evaluate the effects of submitting patients’ PRO-CTCAE results to clinicians prior to consultation on the quality of side-effects management and resultant clinical outcomes. Springer International Publishing 2017-09-12 /pmc/articles/PMC5934932/ /pubmed/29757324 http://dx.doi.org/10.1186/s41687-017-0005-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Baeksted, Christina Pappot, Helle Nissen, Aase Hjollund, Niels Henrik Mitchell, Sandra A. Basch, Ethan Bidstrup, Pernille Envold Dalton, Susanne Oksbjerg Johansen, Christoffer Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients |
title | Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients |
title_full | Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients |
title_fullStr | Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients |
title_full_unstemmed | Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients |
title_short | Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients |
title_sort | feasibility and acceptability of electronic symptom surveillance with clinician feedback using the patient-reported outcomes version of common terminology criteria for adverse events (pro-ctcae) in danish prostate cancer patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934932/ https://www.ncbi.nlm.nih.gov/pubmed/29757324 http://dx.doi.org/10.1186/s41687-017-0005-6 |
work_keys_str_mv | AT baekstedchristina feasibilityandacceptabilityofelectronicsymptomsurveillancewithclinicianfeedbackusingthepatientreportedoutcomesversionofcommonterminologycriteriaforadverseeventsproctcaeindanishprostatecancerpatients AT pappothelle feasibilityandacceptabilityofelectronicsymptomsurveillancewithclinicianfeedbackusingthepatientreportedoutcomesversionofcommonterminologycriteriaforadverseeventsproctcaeindanishprostatecancerpatients AT nissenaase feasibilityandacceptabilityofelectronicsymptomsurveillancewithclinicianfeedbackusingthepatientreportedoutcomesversionofcommonterminologycriteriaforadverseeventsproctcaeindanishprostatecancerpatients AT hjollundnielshenrik feasibilityandacceptabilityofelectronicsymptomsurveillancewithclinicianfeedbackusingthepatientreportedoutcomesversionofcommonterminologycriteriaforadverseeventsproctcaeindanishprostatecancerpatients AT mitchellsandraa feasibilityandacceptabilityofelectronicsymptomsurveillancewithclinicianfeedbackusingthepatientreportedoutcomesversionofcommonterminologycriteriaforadverseeventsproctcaeindanishprostatecancerpatients AT baschethan feasibilityandacceptabilityofelectronicsymptomsurveillancewithclinicianfeedbackusingthepatientreportedoutcomesversionofcommonterminologycriteriaforadverseeventsproctcaeindanishprostatecancerpatients AT bidstruppernilleenvold feasibilityandacceptabilityofelectronicsymptomsurveillancewithclinicianfeedbackusingthepatientreportedoutcomesversionofcommonterminologycriteriaforadverseeventsproctcaeindanishprostatecancerpatients AT daltonsusanneoksbjerg feasibilityandacceptabilityofelectronicsymptomsurveillancewithclinicianfeedbackusingthepatientreportedoutcomesversionofcommonterminologycriteriaforadverseeventsproctcaeindanishprostatecancerpatients AT johansenchristoffer feasibilityandacceptabilityofelectronicsymptomsurveillancewithclinicianfeedbackusingthepatientreportedoutcomesversionofcommonterminologycriteriaforadverseeventsproctcaeindanishprostatecancerpatients |